Alx oncology announces first patient dosed in aspen-03, a phase 2 study of alx148 in combination with keytruda® (pembrolizumab) for the treatment of patients with advanced head and neck squamous cell carcinoma

- the first of two distinct randomized phase 2 studies in collaboration with merck has been initiated

ALXO Ratings Summary

ALXO Quant Ranking